Goldman Sachs Group is a leading global investment banking, securities, and investment management firm that provides a wide range of financial services to a diverse client base, including corporations, financial institutions, governments, and individuals. The company engages in various activities, including financial advisory services, underwriting of capital market transactions, asset management, and market making in securities and commodities. It is known for its expertise in mergers and acquisitions, risk management, and investment strategy, leveraging its extensive research capabilities and global reach to deliver innovative solutions in an ever-evolving financial landscape. Read More
What Happened? A number of stocks fell in the afternoon session after Trump said a US-Iran deal could come in "two or three days," pulling energy equities sh...
Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches.
Speaking at a Gol
Alnylam Pharmaceuticals (NASDAQ:ALNY) executives outlined the company’s 2030 financial targets, TTR franchise strategy and near-term pipeline priorities during a Goldman Sachs event hosted by analyst Salveen Richter.
Jeff Poulton, Alnylam’s chief financial officer, said the company’s “Alnylam 2030”
What Happened? Shares of alternate site health provider Option Care Health (NASDAQ:OPCH) jumped 3.7% in the morning session after Goldman Sachs initiated cov...
Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity.
Speaking at a Goldman Sachs event, Peter
Annexon (NASDAQ:ANNX) executives used a Goldman Sachs Healthcare Conference session to outline the company’s upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the fourth quarter for vonaprument in geographic atrophy, a form of advanced dry age-related macular dege
Major financial institutions remain optimistic about copper prices even as the industrial metal trades close to historic highs, with analysts expecting tight supply and firm demand to keep the market elevated in the months ahead. Among the most bullish is Goldman Sachs, which has raised its year-end copper forecast to $13,735 per ton. This is over 10% higher than its earlier projection of $12,465 per ton.
The global software sector is undergoing a massive structural re-stratification following an unprecedented sell-off in the first quarter of 2026. Data from FactSet revealed that the iShares Expanded Tech-Software Sector ETF (IGV), which tracks North American tech software stocks, plummeted by over 24% in Q1—its sharpest quarterly decline since the 2008 financial crisis.
Goldman Sachs stayed in focus as GS stock traded near $1,045 on June 9, 2026, after another active market session. The stock was recently priced at $1,045.
Bioventus (NASDAQ:BVS) executives outlined the company’s portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT.
Mark Singleton, Bioventus’ senior vice president and chief financi
What Happened? Shares of health insurance company Oscar Health (NYSE:OSCR) jumped 10.8% in the afternoon session after the company provided a business update...
Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate
